Biopharmaceutical royalties buyer Royalty Pharma plc (Nasdaq:RPRX) announced on Thursday that it has acquired a synthetic royalty on US sales of Geron Corporation's (NASDAQ: GERN) RYTELO (imetelstat) for USD125m.
RYTELO is an FDA-approved treatment for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anaemia. Geron is currently enrolling a Phase 3 trial of imetelstat in myelofibrosis patients who are relapsed/refractory to JAK-inhibitors.
This acquisition increases Royalty Pharma's synthetic royalty funding for 2024 to USD925m.
Royalty Pharma will receive tiered royalty payments on RYTELO's US net sales, ranging from 7.75% of annual net sales up to USD500m, and 3.0% of annual net sales between USD500m and USD1bn, to 1.0% of annual net sales over USD1bn. Payments to Royalty Pharma will cease if the aggregate royalties payable through 30 June 2031 reach a multiple of 1.65 its investment, otherwise the royalty payments will continue until Royalty Pharma receives a multiple of 2.0 its investment.
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
TuHURA Biosciences acquires Kineta
AbbVie agrees to acquire Capstan Therapeutics
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer